Excalibur Fund Managers

Neurotech is a biotechnology company focused on developing sight-saving therapeutics for chronic retinal diseases. Their innovative approach involves engineering an ocular implant that continuously produces therapeutic proteins, aiming to improve the quality of life for people with these conditions.

Takeda Cambridge Limited (TCB) and its subsidiary TSP, have established world-class target identification and validation capabilities. Together they have developed a promising pipeline of novel drug discovery targets and compounds in key areas of unmet medical need such as CNS disorders, chronic pain and urology indications, endocrinology and metabolic-related diseases.

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines.

Intercytex Group plc is a biotechnology company based in Cambridge, UK, that specializes in the research, development, and commercialization of cell-based therapies aimed at repairing and regenerating skin and hair. Founded in 2000, the company utilizes an integrated cell technology platform to create living, human cell-based products. Its notable product developments include VAVELTA, aimed at facial rejuvenation and skin damage repair, which has completed Phase II trials; ICX-TRC, a hair regeneration therapy that also completed Phase II trials; and ICX-SKN, a skin graft replacement for burns and acute wounds, which has completed Phase I trials. Additionally, Intercytex is working on ICX-RHY, a therapy intended to address skin-related conditions such as epidermolysis bullosa and scar contractures.

Takeda Cambridge Limited (TCB) and its subsidiary TSP, have established world-class target identification and validation capabilities. Together they have developed a promising pipeline of novel drug discovery targets and compounds in key areas of unmet medical need such as CNS disorders, chronic pain and urology indications, endocrinology and metabolic-related diseases.

Destination Skin Limited operates a network of clinics across the United Kingdom, specializing in laser hair removal and various skincare services for both women and men. Established in 2003 and headquartered in Swindon, the company provides complimentary consultations to recommend tailored treatments for individual skin concerns, such as acne, ageing skin, pigmentation, and excessive sweating. Their extensive range of services includes laser hair removal, anti-wrinkle injections, microdermabrasion, and skin rejuvenation, among others. In addition to clinical treatments, Destination Skin offers a selection of skincare products and tools through its online shop. The company has established a presence in major cities, including London, Birmingham, and Manchester, ensuring accessibility to its diverse clientele.

Plethora Solutions Holdings is a specialty pharmaceutical company focused on developing and marketing products for the treatment and management of urological disorders. It addresses a growing market characterized by significant unmet medical needs, which presents strong commercial opportunities for innovative pharmaceutical solutions. The company's main offering is a treatment for male premature ejaculation, which received marketing authorization from the European Commission in November 2013. Plethora Solutions is committed to enhancing patient outcomes through its specialized products, aiming to improve the quality of life for individuals affected by urological conditions.

Neurotech is a biotechnology company focused on developing sight-saving therapeutics for chronic retinal diseases. Their innovative approach involves engineering an ocular implant that continuously produces therapeutic proteins, aiming to improve the quality of life for people with these conditions.

Ardana Bioscience was created in July 2000 to commercialise research by the Medical Research Council (MRC )'s Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland which has been at the forefront of this area of research for the last 28 years. The MRC employs nearly 100 staff at the Unit which currently receives total annual funding of £3.8 million.

Piramed Limited, a biotech company, discovers and develops new medicines for the treatment of cancer and immune inflammatory disorders. The company focuses on the discovery and development of inhibitors to find clinical utility in various diseases, including cancer, immune inflammatory disorders, cardiovascular disease, and pain, as well as metabolic and infectious diseases. The company was incorporated in 2001 and is based in Slough, the United Kingdom. As of May 23, 2008, Piramed Limited operates as a subsidiary of Hoffmann-La Roche Inc.

Energist Ltd specializes in the design, manufacture, marketing, and supply of lasers and light-based systems for hair removal and aesthetic skin treatments within the medical and beauty sectors. The company offers a range of products, including variable and intense pulsed light systems for hair removal and skin rejuvenation, as well as laser systems such as light emitting diode (LED) and CO2 lasers for medical and surgical applications. Additionally, Energist provides LED systems and micro-needle rollers aimed at anti-aging treatments. Its products cater to various aesthetic and surgical needs, including vascular treatments, skin rejuvenation, resurfacing, and regeneration. Energist sells its products both directly and through a network of distributors globally. Founded in 1999, the company is headquartered in Swansea, United Kingdom, and operates as a subsidiary of Energist Medical Group.

Arakis Limited is a company dedicated to the discovery and development of medicinal products, with a focus on inflammatory diseases and oncology adjunctive therapies. The firm specializes in researching cytokine and receptor-mediated mechanisms of disease, allowing it to identify and develop new clinical applications for established drugs and drug templates. By leveraging known medicines, Arakis aims to create performance-enhanced therapies, addressing unmet medical needs in its targeted therapeutic areas, which include inflammatory disease and pain management.

Microscience is a biotechnology company established in 1997 that specializes in the discovery and development of innovative vaccines for the prevention and treatment of diseases with significant unmet clinical needs. The company leverages its expertise in functional genomics and proteomics to create proprietary vaccines and immunotherapeutics. Microscience boasts a robust intellectual property portfolio, including three granted patents and numerous additional patents covering over 300 genes and targets, which supports its product development and ensures long-term protection beyond projected product launch dates.

Ardana Bioscience was created in July 2000 to commercialise research by the Medical Research Council (MRC )'s Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland which has been at the forefront of this area of research for the last 28 years. The MRC employs nearly 100 staff at the Unit which currently receives total annual funding of £3.8 million.

EpiCept Corporation, headquartered in Englewood Cliffs, New Jersey, with a subsidiary in Munich, Germany, specializes in the development of innovative pharmaceutical products aimed at treating pain and cancer. The company focuses on creating safe and effective prescription pain management solutions that utilize a topical delivery system, distinguishing itself from traditional systemic or transdermal methods. EpiCept is committed to exploring partnerships for co-marketing, co-promotion, licensing, and distribution with third-party collaborators to expand its reach in the market. The company's products are supported by a robust patent portfolio, reflecting its dedication to protecting its innovations and capitalizing on the significant market potential of its offerings.

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines.

Founded in 1997, TME Pharma is a Berlin-based biopharmaceutical company specializing in the development of biostable aptamers and substances derived from mirror image nucleic acids. Its lead product, NOX-A12, targets the tumor microenvironment to enhance cancer therapy effectiveness.

Microscience is a biotechnology company established in 1997 that specializes in the discovery and development of innovative vaccines for the prevention and treatment of diseases with significant unmet clinical needs. The company leverages its expertise in functional genomics and proteomics to create proprietary vaccines and immunotherapeutics. Microscience boasts a robust intellectual property portfolio, including three granted patents and numerous additional patents covering over 300 genes and targets, which supports its product development and ensures long-term protection beyond projected product launch dates.

Arakis Limited is a company dedicated to the discovery and development of medicinal products, with a focus on inflammatory diseases and oncology adjunctive therapies. The firm specializes in researching cytokine and receptor-mediated mechanisms of disease, allowing it to identify and develop new clinical applications for established drugs and drug templates. By leveraging known medicines, Arakis aims to create performance-enhanced therapies, addressing unmet medical needs in its targeted therapeutic areas, which include inflammatory disease and pain management.

Microscience is a biotechnology company established in 1997 that specializes in the discovery and development of innovative vaccines for the prevention and treatment of diseases with significant unmet clinical needs. The company leverages its expertise in functional genomics and proteomics to create proprietary vaccines and immunotherapeutics. Microscience boasts a robust intellectual property portfolio, including three granted patents and numerous additional patents covering over 300 genes and targets, which supports its product development and ensures long-term protection beyond projected product launch dates.

BioVex Group is a biotechnology company specializing in the development and commercialization of biological treatments for cancer and infectious diseases. Its primary focus is OncoVEXGM-CSF, an oncolytic vaccine designed to target and destroy cancer cells while preserving surrounding healthy tissues. This innovative therapy utilizes a virus that replicates within solid tumors, leading to their destruction and stimulating a robust systemic immune response against the cancer. OncoVEXGM-CSF has undergone extensive clinical testing with over 110 patients across various solid tumors, including melanoma, head and neck cancer, breast cancer, and pancreatic cancer. The treatment has demonstrated significant efficacy, routinely eliminating tumors at the injection site and resulting in overall disease responses during Phase II trials. Additionally, BioVex is developing ImmunoVEXHSV2, a vaccine aimed at preventing genital herpes, further expanding its portfolio in biologic therapies.

Vectura Group specializes in developing pharmaceutical therapies for treating airways-related diseases such as asthma and COPD. With a focus on inhalation products, the company offers formulation, development, manufacturing services, and integrated platforms to improve patient outcomes in this $30 billion global market.

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted medicines for cancer and other proliferative diseases. Founded in 1996 by Professor Sir David Lane, the company focuses on oral therapies that target various phases of cell cycle control.

ReNeuron Group is a biotechnology company based in Pencoed, United Kingdom, specializing in the research and development of cell-based therapies for various medical conditions. Founded in 1997, it is primarily focused on developing innovative treatments for stroke disability and inherited retinal diseases, including its CTX stem cell therapy candidate, which is currently undergoing Phase IIb clinical trials, and its human retinal progenitor cell therapy, which is in Phase I/IIa trials for retinitis pigmentosa. The company is also exploring the therapeutic potential of CTX-derived exosomes, which are nano-sized packages of information released by CTX cells. Additionally, ReNeuron has established a research agreement with a U.S. biotechnology firm to collaborate on novel gene silencing-based therapeutics. Through its advanced product pipeline and strategic partnerships, ReNeuron aims to address significant unmet medical needs in the therapeutic landscape.